Article info

Download PDFPDF

Original article
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic

Authors

  • Katie L Druce Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK PubMed articlesGoogle scholar articles
  • Kundan Iqbal Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, UK PubMed articlesGoogle scholar articles
  • Kath D Watson Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK PubMed articlesGoogle scholar articles
  • Deborah P M Symmons Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK PubMed articlesGoogle scholar articles
  • Kimme L Hyrich Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, UK PubMed articlesGoogle scholar articles
  • Clive Kelly Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Clive Kelly; katie.druce{at}manchester.ac.uk
View Full Text

Citation

Druce KL, Iqbal K, Watson KD, et al
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic

Publication history

  • Received April 3, 2017
  • Revision received May 18, 2017
  • Accepted June 6, 2017
  • First published July 13, 2017.
Online issue publication 
July 13, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.